WAGENINGEN, the Netherlands, May 8 /PRNewswire/ -- Dafra Pharma has commissioned Plant Research International
(PRI) to begin new research into optimising the production method of
artemisinin via genetically modified chicory plants. The aim of the research
is to realize inexpensive, large-scale production of artemisinin under
controllable conditions. Artemisinin is a basic raw material used in ACTs
(Artemisinin-based Combination Therapies), the latest generation and most
effective antimalarial treatment according to the WHO.
Malaria and ACTs
According to WHO, some 300 to 500 million cases of malaria and
Some 1.5 to 2 million deaths occur annually due to malaria worldwide, of
which 90% in Africa. Every 30 seconds one child dies of malaria in Africa.
And yet malaria is perfectly treatable. Rapid diagnosis and treatment
with an ACT can conquer the disease before it becomes life-threatening. Since
the malaria parasite has become resistant to the older, more conventional
antimalarial treatments, such as chloroquine, SP etc, WHO recommends ACTs as
the first-line treatment in African countries. However, artemisinin is an
expensive plant extract, which means that an ACT can currently easily cost 10
times more than treatment with, say, chloroquine. ACTs are very expensive for
African patients. This means that the price of ACTs - and therefore the price
of artemisinin - needs to drop sharply.
Biosynthetic production of artemisinin via plants
Earlier research done by Dafra Pharma (Belgian pharmaceutical
company that is private market leader in Afrika for ACT's) and Plant Research
International (PRI) (University of Wageningen, the Netherlands) showed in a
wide range of plant species that the diversion of the biosynthesis of the
enzymes in chicory, involved in the production of the bitter compounds, can
be carried out very efficiently.
New research by PRI, also commissioned by Dafra Pharma, now aims to
examine how the artemisinin precursor (dihydroartemisininic acid) can be
optimally extracted from the chicory root. With its chemical experience and
know-how, Dafra Pharma can, after extraction, convert the precursor into
artemisinin, which can be used to produce ACTs.
Industrial scaling-up for a humane cause
To free Africa from malaria - the slogan for World Malaria Day
2007 - some 400 million treatments per year will be needed. Accordingly, PRI
and Dafra Pharma will continue their close cooperation in the optimization of
the biosynthesis technology for the industrial production of artemisinin.
PRI and Dafra Pharma have opted to use inuline chicory as artemisinin
production platform. The advantage of this industrial (i.e. non-food) crop is
that the entire chain - from large-scale agricultural production up to and
including extraction - is already in place in both Belgium and the
Netherlands.
Dr FH Jansen, R&D Manager at Dafra Pharma, states it must the objective
of Dafra Pharma to achieve inexpensive, large-scale industrial production of
artemisinin via chicory roots in 3 to 5 years time.
This new inexpensive basic raw material should enable Dafra Pharma
International to bring future ACTs to market at a price of half a dollar per
adult antimalarial treatment.
Dafra Pharma Ltd
Dafra Pharma is a Belgian family-owned pharmaceutical company
and is the private-sector market leader across Africa for artemisinin-based
combination antimalarial therapies. Dafra Pharma has built up a unique
distribution and promotional network in 36 African countries with currently
more than 120 local African medical representatives. Since its founding in
1997, Dafra Pharma has focused on research and development in medicines for
"neglected tropical diseases", such as malaria, sleeping sickness,
schistosomiasis, TBC, leishmaniasis and others.
Plant Research International
Plant Research International is part of Wageningen UR
(Netherlands) and is the most important Dutch research institute for
scientific research on plants. The institute develops and uses genetic
modification for research on sustainable agriculture, healthy food and a safe
environment.